AI assistant
OptimizeRx Corp — Director's Dealing 2022
Jan 3, 2022
33090_dirs_2022-01-03_43e04e86-72a0-47a0-9f95-5b8ba9a11d34.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 4 — Statement of Changes in Beneficial Ownership
Issuer: OptimizeRx Corp (OPRX)
CIK: 0001448431
Period of Report: 2021-12-30
Reporting Person: HALAS GUS D (Director)
Derivative Transactions
| Date | Security | Exercise Price | Code | Shares | A/D | Expiration | Underlying | Ownership |
|---|---|---|---|---|---|---|---|---|
| 2021-12-30 | Restricted Stock Units | $ | A | 409 | Acquired | Common Stock (409) | Direct |
Footnotes
F1: Each restricted stock unit represents a contingent right to receive one share of the issuer's common stock.
F2: Grant to the Reporting Person of restricted stock units under the OptimizeRx Corp. 2021 Equity Incentive Plan. The restricted stock units granted vest on December 30, 2022, subject to continued service to the issuer through the vesting date. This restricted stock units granted are subject to accelerated vesting in the event that the recipient is subject to a qualified termination within a specified period of time prior to or following the closing of a change in control transaction.
F3: Not applicable.